DOR BioPharma Inc.

Dr. Schaber previously served as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was employed for the last ten years with responsibility for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. Prior to working at Discovery, Dr. Schaber was employed by Ohmeda PPD, Inc. as Worldwide Director of Regulatory Affairs and Operations from 1994 to 1996. While at Ohmeda, Dr. Schaber was responsible for all strategies related to the regulatory requirements of the FDA and international health authority bodies and was credited with the successful New Drug Application ("NDA") for INOmax (inhaled nitric oxide) for the treatment of persistent pulmonary hypertension of the newborn that was subsequently approved by the FDA. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions of increasing importance with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his B.A. from Western Maryland College, an M.S. in Pharmaceutics from Temple University School of Pharmacy, and a Ph.D. in Pharmaceutical Sciences from The Union Graduate School. Dr. Schaber also holds a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society. Dr. Schaber has most recently served as an NDA and FDA regulatory strategic advisor to DOR.

Mr. Evan Myrianthopoulos has been a director of DOR since 2002 and is currently the chief financial officer (CFO) after joining the Company in November 2004 as president and acting CEO. From November 2001 to November 2004, Evan was president and founder of CVL Advisors, Group, Inc., a financial consulting firm specializing in the biotechnology sector. Prior to founding CVL Advisors Group, Inc., Mr. Myrianthopoulos was a co-founder of Discovery Laboratories. During his tenure at Discovery from June 1996 to November 2001, Mr. Myrianthopoulos held the positions of CFO and vice president of finance, where he was responsible for raising approximately $55 million in four private placements. He also helped negotiate and manage Discovery's mergers with Ansan Pharmaceuticals and Acute Therapeutics. Prior to co-founding Discovery, Mr. Myrianthopoulos was a technology associate at Paramount Capital Investments, LLC, a New York City-based biotechnology venture capital and investment banking firm. Prior to joining Paramount Capital, Mr. Myrianthopoulos was a managing partner at a hedge fund, and also held senior positions in the treasury department at the National Australia Bank where he was employed as a spot and derivatives currency trader. Mr. Myrianthopoulos holds a B.S. in economics and psychology from Emory University.

Brings 15 years of senior financial management experience, involving both domestic and international entities, and participating in over $100 Million in equity and debt financing. Prior to joining DOR, Mr. Clavijo, held the position of Chief Financial Officer for Cigarette Racing Team (Miami, FL). During his time with Cigarette he was instrumental in developing a cost accounting manufacturing tracking system and managed the administration and development of an IRB Bond related to a 10 acre, 100,000 square foot facility purchase. Mr. Clavijo has also held positions as Chief Financial Officer and Corporate Controller for both private and public companies in the manufacturing and repair industries. As corporate controller, for A Novo Broadband, he managed several mergers and acquisitions and corporate restructuring. He also, held the position of Finance Manager for Wackenhut Corporation in the U.S. Governmental Services Division. In addition, he served in the U.S. Army from 1983 to 1996 in both a reserve and active duty capacity for personnel and medical units. Mr. Clavijo holds a Master in Accounting degree from Florida International University, a Bachelor in Accounting degree from the University of Nebraska, and a Bachelor in Chemistry degree from the University of Florida. Mr. Clavijo is a licensed Certified Public Accountant in the state of Florida.

Rosen is responsible for developing marketing strategies for Forest City's biotech projects across the United States, including the Science + Technology Park at Johns Hopkins and the Illinois Science + Technology Park. He also serves as Forest City's liaison to the life science industry developing ongoing day-to-day working relationships with Forest City's biotech/research clients and establishes contacts with other prospective emerging technology prospects. He holds a BA degree in International Relations from Beloit College, and an MBA degree in International Business from the University of Miami (Florida).